---
title: "RBC Capital Remains a Buy on GH Research (GHRS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295289688.md"
description: "RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research (GHRS) with a $42 price target on August 6, noting the stock closed at $30.64. This aligns with a Strong Buy consensus and a Cantor Fitzgerald Buy rating ($40 target), suggesting significant upside potential for the healthcare sector stock."
datetime: "2026-08-08T01:45:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295289688.md)
  - [en](https://longbridge.com/en/news/295289688.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295289688.md)
generator: "portal-rs"
---

# RBC Capital Remains a Buy on GH Research (GHRS)

RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on August 6 and set a price target of $42.00. The company’s shares closed yesterday at $30.64.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Abrahams covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biogen, and Neurocrine. According to TipRanks, Abrahams has an average return of 14.3% and a 56.11% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for GH Research with a $43.50 average price target, a 41.97% upside from current levels. In a report released on August 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)

## Related News & Research

- [8,918 Shares in Guardant Health, Inc. $GH Bought by B. Metzler seel. Sohn & Co. AG](https://longbridge.com/en/news/296750019.md)
- [Guardant Health Insider Move: Director Trims Stake in Latest Stock Sale](https://longbridge.com/en/news/296297912.md)
- [Morgans Sticks to Its Buy Rating for IPH Ltd. (IPH)](https://longbridge.com/en/news/296572621.md)
- [Guardant Health to Appeal Federal District Court Judgment | GH Stock News](https://longbridge.com/en/news/296820317.md)
- [Bernstein Sticks to Its Hold Rating for ABB Ltd (0NX2)](https://longbridge.com/en/news/296586048.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**